Mondrian Investment Partners 13F: Cuts TMO Stake by $127M

Mondrian Investment Partners reduced its stake in Thermo Fisher Scientific Inc. (NYSE: TMO) by 188,806 shares, according to a Form 13F filing on October 23, 2026. The fund ended the quarter with 157,456 shares valued at approximately $106.3 million.

TMO Thermo Fisher Scientific Inc.

$673.82 ▲ +14.04% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Mondrian Investment Partners's Thermo Fisher Scientific Inc. Position

The fund cut its position by 54.5% during the period, moving down from its previous holding of 346,262 shares. The remaining stake leaves the fund with a smaller foothold in the laboratory products provider as institutional adjustments continue across the healthcare sector.

Other Institutional Activity in Thermo Fisher Scientific Inc.

Franklin Resources, Inc. grew its holdings by 458,515 shares, ending with 7,271,514 shares worth about $4.9 billion.

Thermo Fisher Scientific Inc. Stock Down 2.5%

Thermo Fisher Scientific closed at $673.82 on October 23, 2026, and recently traded around $676.54 as of October 24, 2026. The stock sits below its 52-week high of $705.79 and well above its 52-week low of $435.27. Shares trade comfortably above both their 50-day moving average of $643.40 and their 200-day moving average of $548.99.

Recent Earnings

Thermo Fisher Scientific reported trailing twelve-month revenue of $47.35 billion alongside earnings of $18.96 per share. The company posted a net profit margin of 14.9% and a return on equity of 13.4%, with year-over-year revenue growth coming in at 9.1%. The next earnings report is scheduled for January 28, 2027.

Dividend

The company pays an annual dividend rate of $1.88 per share, which translates to a dividend yield of 0.28% based on recent trading levels. This payout utilizes 9.7% of the company's earnings.

Insider Buying and Selling at Thermo Fisher Scientific Inc.

Lisa P. Britt sold 11,440 shares on August 19, 2026, at an average price of $613.12 for a total value of about $7.0 million. Chief Executive Officer Marc N. Casper sold 20,000 shares on August 21, 2026, valued at approximately $12.6 million, followed by another sale of 275 shares on August 24, 2026, worth $172,439. Gianluca Pettiti sold 4,133 shares on August 31, 2026, at an average price of $614.38 for a total of roughly $2.5 million.

Analysts Set New Price Targets

On October 22, 2026, Barclays maintained its Overweight rating while lifting its price target from $750.00 to $775.00. RBC Capital maintained a Sector Perform rating on the same day and raised its target from $580.00 to $730.00. TD Cowen maintained a Buy rating on October 22, 2026, raising its target from $760.00 to $810.00, and Stifel kept a Buy rating while moving its target from $650.00 to $775.00. Citigroup maintained a Buy rating on October 23, 2026, raising its target to $800.00 from $685.00. Across the broader analyst community, the stock holds a consensus recommendation key of strong_buy with a mean price target of $750.92.

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products. The company supports biopharma services and international research efforts through four primary segments, serving healthcare and scientific institutions worldwide.

Bottom Line

Investors will look toward the upcoming earnings release on January 28, 2027, for further updates on financial performance. Institutional shifts and ongoing analyst revisions will continue to shape market sentiment around the healthcare provider.